Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3255 USD | -0.18% | -15.01% | -93.79% |
May. 21 | Lyra Therapeutics Reduces Workforce to Extend Cash Runway | MT |
May. 21 | Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital | CI |
Financials (USD)
Sales 2024 * | 1.58M | Sales 2025 * | 807K | Capitalization | 19.84M |
---|---|---|---|---|---|
Net income 2024 * | -87M | Net income 2025 * | -86M | EV / Sales 2024 * | 12.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 24.6 x |
P/E ratio 2024 * |
-0.26
x | P/E ratio 2025 * |
-0.31
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.37% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -0.18% | ||
1 week | -15.01% | ||
Current month | -93.69% | ||
1 month | -93.78% | ||
3 months | -93.86% | ||
6 months | -88.70% | ||
Current year | -93.79% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 0.3255 | -0.18% | 2,900,474 |
24-05-23 | 0.3261 | -4.73% | 3,538,018 |
24-05-22 | 0.3423 | -3.69% | 2,693,430 |
24-05-21 | 0.3554 | -4.72% | 4,831,703 |
24-05-20 | 0.373 | -2.61% | 3,330,345 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-93.79% | 19.84M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- LYRA Stock